

ASX: CVB

28 January 2025

Commercial Agreement with Stryker expanded to Australia & New Zealand

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX:CVB, “CurveBeam AI” or the “Company”), a fully integrated developer and manufacturer of point-of-care specialised weight bearing CT imaging (WBCT) equipment, is pleased to announce that it has signed a commercial agreement (‘Referral Agreement’) with Stryker Australia Pty Ltd for the territories of Australia and New Zealand.

Under the agreement, Stryker will provide direct education of surgeons and promotion of CurveBeam AI’s HiRise for use in lower extremity orthopaedic applications. This is targeted to increase the demand for WBCT scans through improved surgeon awareness and understanding of the benefits of WBCT.

The agreement is exclusive for the territory, has an initial term of 3 years, and a further term of 2 years, and has minimum volumes for referrals that result in a sale and commission in order for the exclusive agreement to continue.

Stryker has a 25+ person sales organisation in this region which can assist in the education of local surgeons to the benefits of weight bearing CT and for the direct referral of sales opportunities to CurveBeam AI.

CurveBeam AI will then conclude sales directly with customers in the Australian and New Zealand markets, being imaging centres and hospitals that can use the HiRise Weight Bearing CT Scanner to support improved diagnosis and surgical planning.

The Company’s previous distribution agreement for the Australian market with a local distributor expired in 2024, and CurveBeam AI sees this agreement as a material expansion of its market opportunity in Australia and New Zealand.

CurveBeam AI CEO Greg Brown said “We are very excited to expand this relationship to our home market, and are in fact well down the road with the Stryker Australia and New Zealand leadership team in preparing a launch with extensive education programs around the benefits of WBCT through the HiRise. Stryker’s scale, resources and reach, along with the fact that the collaboration is very synergistic, will be all instrumental in driving surgeon demand for WBCT. We see this demand being met through placing HiRise WBCT scanners with imaging centres and hospitals.”

Release approved by the Board

About CurveBeam AI Limited

CurveBeam AI Limited (ABN 32 140 706 618) (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company’s flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or

MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

CEO and Managing Director:

Greg Brown
info@curvebeamai.com

Investor / media enquiries contact:

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au